Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

Table 4 Percentage of patients experiencing pneumonia events, stratified by treatment at baseline and last visit proximate to event

	Treatment
	FP	Other ICS	No ICS
Patients with first pneumonia event (%)
Treatment at baseline	15.5	13.8	12.7
Treatment at last visit before event^a	12.9	10.1	8.6
First hospitalized pneumonia event (%)
Treatment at baseline	10.5	8.5	7.5
Treatment at last visit before event^a	8.3	6.6	5.2
Pneumonia event resulting in death (%)
Treatment at baseline	0.6	1.3	1.1
Treatment at last visit before event^a	0.6	0.9	0.7

Abbreviations: FP fluticasone propionate, ICS inhaled corticosteroid. Patients were matched at baseline (matched subgroup by baseline ICS use population, N = 4002). ^aPercentages are calculated as patients with pneumonia events / patients taking treatment at any time prior to the event or, in those without event, at any time during the study

ISSN: 1465-993X